SCHEMBL25015299

SCHEMBL25015299

CC(=O)OCCSc1ccc(C#Cc2ccc(CSc3ccc(C#Cc4ccc(SCCOC(C)=O)cc4)cc3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.43
MAOA P21397 4/20 0.43
ACACB O00763 3/20 0.39
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
APP P05067 1/20 0.37
MAPK1 P28482 1/20 0.37
STAT3 P40763 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25015298 0.83 FFAR1 (0.43) ACACBALDH1A1HTT
SCHEMBL25015312 0.80 MTNR1A (0.35) ACACBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL25015308 0.80 GABRA1 (0.35) ACACBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL25015310 0.79 MTNR1A (0.38) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL25015144 0.79 FFAR1 (0.35) ACACBMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL25015146 0.75 PPARD (0.40) ACACBMEN1KMT2APPARA
SCHEMBL27858437 0.75 HSP90AA1 (0.45) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL1710082 0.75 ALDH1A1 (0.49) SMN1; SMN2RAB9ANPC1MAPTLMNA
SCHEMBL25015143 0.74 PPARA (0.41) ACACBAPPPPARA
SCHEMBL13034077 0.73 RAB9A (0.54) MEN1KMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230042009-A1 COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT FUJIFILM CORPORATION (JP) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230042009-A1 COMPOUND, COMPOSITION, CURED SUBSTANCE, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT SP1, C5, ZYX MAOB 3375/4885MAOA 3781/4885ACACB 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.